MASSDEVICE ON CALL — Results from the one of the 1st in-human studies of transcatheter aortic valve implants proved that the devices remained durable and effective 5 years after treatment, researchers found.
The study, which included 111 patient implanted with either Edwards Lifesciences (NYSE:EW) Sapien valve or the Cribier-Edwards valve, was the 1st study of transapical and transarterial TAVI devices in inoperable patients, TheHeart.org reported.
Researchers reported that the early TAVI systems may be as durable as traditional surgical valve implants.
The study had a high early mortality rate, but the deaths were unrelated to valve deterioration, according to the study. The patients selected for the study were an average of 83 years old and high rates of related co-morbidities, according to Heartwire.
GE recalls resuscitator components
Healthcare giant GE Healthcare (NYSE:GE) initiated a voluntary recall of a T-piece component used with its Giraffe and Panda resuscitation units over concerns that the pieces may not be able to achieve peak inspiratory pressure.
Read more
Biogen takes Baxter’s spot on the S&P 500
Medical device maker Biogen Idec (NSDQ:BIIB) beat out Baxter (NYSE:BAX) to take the #163 spot on the S&P 500.
Read more
Supreme Court won’t stand in the way of Obamacare contraception mandate
The nation’s highest court ruled this week not to block the birth control mandate contained in President Barack Obama’s Affordable Care Act, refusing a motion filed by craft store chain Hobby Lobby and its Catholic owners.
Read more
